TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction.
The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at ERS International Congress 2021, 5-8 September 2021.
- How much of a problem is OCS dependency in severe asthma? (0:12)
- Could you tell us a little about the PONENTE study and its findings to date? (0:45)
- What are the implications of these findings for the severe asthma treatment landscape? (1:58)
- What will be the next steps in your research? (2:46)
Disclosures: Andrew Menzies-Gow discloses attending advisory boards for Astra Zeneca, Sanofi, Novartis and Glaxo SmithKline; Receiving speaker fees from AZ, Novartis, Teva and Sanofi; and has participated in research with AZ.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
Share this Video
Related Videos In Asthma
Barbara Yawn, CHEST 2022: The role of respiratory specialists in herpes zoster vaccination
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. We caught up with Dr. Barbara Yawn (University of Minnesota, […]
Barbara Yawn, CHEST 2022: Herpes zoster vaccination in people with asthma or chronic obstructive pulmonary disease
Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. touchRESPIRATORY were delighted to speak with Dr. Barbara Yawn (University […]
Cristiano Caruso, ERS 2022: 2 Year Findings from the REALITI-A Study of Mepolizumab in Severe Asthma
REALITI-A was an international, prospective, observational cohort study, investigating the real-world corticosteroid-sparing effect of mepolizumab in severe asthma. touchRESPIRATORY caught up with Dr. Cristiano Caruso (Columbus Hospital, Fondazione Policlinico A. Gemelli, IRCCS, Rome, Italy) to discuss the aims, design, eligibility criteria and the 2 year findings from REALITI-A. The abstract ‘International, prospective study of mepolizumab […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!